Table 2.
Dose | 150 mg (n = 2) | 200 mg (n = 5) | 250 mg (n = 4) | 300 mg (n = 17) | Total N (%) |
---|---|---|---|---|---|
Rash | 0 | 0 | 2† | 3† | 5 (17.9%) |
Pruritus | 1 | 0 | 0 | 2 | 3 (10.7%) |
Skin chapped | 0 | 1 | 0 | 1 | 2 (7.1%) |
Liver function abnormal | 2 | 2 | 3 | 3 | 10 (35.7%) |
Nausea/vomiting | 1 | 0 | 1 | 1 | 3 (10.7%) |
Abdominal distention | 0 | 1 | 0 | 2 | 3 (10.7%) |
Loss of appetite | 0 | 1 | 0 | 0 | 1 (3.6%) |
Constipation | 0 | 0 | 0 | 1 | 1 (3.6%) |
Diarrhea | 0 | 1 | 0 | 9† | 10 (35.7%) |
Neutropenia | 0 | 1 | 1 | 2 | 4 (14.3%) |
Thrombocytopenia | 0 | 1 | 1 | 0 | 2 (7.1%) |
Interstitial lung disease | 0 | 0 | 0 | 1† | 1 (3.6%) |
One of the adverse effect was grade 3 in each group, respectively.